How much funding has Receptos raised?

Receptos has raised $35.8M in total funding, most recently a Venture Round.

Who are Receptos's investors?

Receptos's investors include ARCH Venture Partners, Venrock, Polaris Partners, Flagship Pioneering, Eli Lilly.

Where is Receptos headquartered?

Receptos is headquartered in San Diego, California, United States.

What industry is Receptos in?

Receptos operates in Biotech, Drug Discovery, Healthcare, Therapeutics.

Receptos

Closed

San Diego, United States · Founded 2009 · $35.8M raised

Headquarters: San Diego, California
Employees: 51–200
Founded: 2009
Business Model: B2B

Website: receptos.com
Total Funding: $35.8M
Last Round: $10.8M Venture RoundMar 2012
Rounds: 2

About

Receptos was a San Diego-based biopharmaceutical company specializing in immunology and metabolic disease drug discovery and development. Its lead compound, ozanimod (RPC1063), was a selective S1P receptor modulator in clinical trials for multiple sclerosis and ulcerative colitis. Founded in 2009 and based in San Diego, California, Receptos went public and built a pipeline around GPCR-targeted small-molecule therapies. The company was acquired by Celgene Corporation in July 2015 for approximately $7.2–7.3 billion, one of the largest biotech acquisitions of that year. Receptos subsequently became a wholly-owned subsidiary of Celgene, and later of Bristol Myers Squibb following Celgene's acquisition. Ozanimod was eventually approved by the FDA as Zeposia.

Summary

Receptos is a Biotech company based in San Diego, United States, founded in 2009. It has raised $35.8M in total across 2 rounds, most recently a $10.8M Venture Round round in Mar 2012. Investors include ARCH Venture Partners, Venrock and Polaris Partners.